In this study, the authors report the molecular characterization of orally bioavailable and blood-brain-barrier permeable inhibitors of the nuclear export molecule Xpo1/CRM1 and define the immunomodulatory and neuroprotective effects in preclinical models of inflammatory demyelination and excitatory neurotoxicity.
- Jeffery D Haines
- Olivier Herbin
- Patrizia Casaccia